MDxHealth SA (NASDAQ:MDXH) Given Consensus Rating of “Moderate Buy” by Brokerages

MDxHealth SA (NASDAQ:MDXH) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $7.75.

MDXH has been the subject of a number of research reports. BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of MDxHealth in a research note on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. TD Cowen lifted their target price on MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Finally, Lake Street Capital boosted their price target on MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a report on Thursday, November 13th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MDXH. Lido Advisors LLC bought a new stake in shares of MDxHealth during the 3rd quarter valued at about $48,000. GSA Capital Partners LLP acquired a new position in MDxHealth in the third quarter valued at approximately $48,000. Jefferies Financial Group Inc. bought a new position in shares of MDxHealth during the third quarter valued at approximately $53,000. Hudson Bay Capital Management LP acquired a new stake in shares of MDxHealth during the 3rd quarter worth approximately $70,000. Finally, Bank of America Corp DE raised its position in shares of MDxHealth by 5,164.0% during the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares during the period.

MDxHealth Trading Down 2.1%

MDXH stock opened at $3.71 on Tuesday. The firm has a 50 day simple moving average of $3.48 and a 200-day simple moving average of $3.59. The company has a market capitalization of $175.45 million, a P/E ratio of -5.80 and a beta of 1.62. MDxHealth has a twelve month low of $1.35 and a twelve month high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to the consensus estimate of $24.11 million. MDxHealth had a negative net margin of 30.50% and a negative return on equity of 1,078.01%. On average, research analysts predict that MDxHealth will post -1.15 EPS for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.